Genscript Biotech's (HKG:1548) attributable loss widened to $175.1 million in the first half from $93.6 million in the year-ago period, according to a Friday filing with the Hong Kong Stock Exchange.
Loss per share at the biopharmaceutical company widened to $0.0827 from $0.0444 in the previous year. Analysts at Visible Alpha estimated loss per share at $0.04.
Revenue grew to $561.4 million from $391.3 million a year earlier. Visible Alpha analysts forecast revenue at $540.1 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments